About: Prognosticaly stratified treatment of diffuse large B-Cell lymphoma: 13 years of the Moravian experience

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prognosticaly stratified treatment of diffuse large B-Cell lymphoma: 13 years of the Moravian experience Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Intensive chemoterapy significantly improve three-year progresion free surfoval and overal surfoval of intermediate-risk and high-risk patiens younger than 65 years (PFS 85% and 72%, OS 77% and 79%), compared with historical datas. Athe addition of rituximab to chemotherapy significantly decreased the probability of relaps in the whole file, and impovement three-year PFS and OS. Age, IPI, the use of rituximab and achieve CR have an impact n the length of PFS. Multivariete analysis also showed that the use of rituximab with foresight octuple oriented therapy reduced risk of death in patiens with diffuse large B-cell lymphoma. Intensive chemoterapy significantly improve three-year progresion free surfoval and overal surfoval of intermediate-risk and high-risk patiens younger than 65 years (PFS 85% and 72%, OS 77% and 79%), compared with historical datas. Athe addition of rituximab to chemotherapy significantly decreased the probability of relaps in the whole file, and impovement three-year PFS and OS. Age, IPI, the use of rituximab and achieve CR have an impact n the length of PFS. Multivariete analysis also showed that the use of rituximab with foresight octuple oriented therapy reduced risk of death in patiens with diffuse large B-cell lymphoma. (en) Intezifikovaná a intenzivní chemoterapie singinfikantně vyšuje 3-leté přežití do doby progrese (PFS) a všeobecné přežití (OS) středně rizikových a vysoko rizikových skupin pacientů mladších 65 let. Přidání rituximabu do chemoterapie signifikantně znižuje pravděpodobnost relapsu a zvyšuje 3-leté přežití (PFS, OS) všetkých takhle léčených pacientů. Prognosticky stratifikovaná léčba a přidání rituximabu markantně zvyšuje PFS a OS u pacientů s DLBCL léčených na Hemato-onkologické klinice v Olomouci. (cs)
Title	Prognosticaly stratified treatment of diffuse large B-Cell lymphoma: 13 years of the Moravian experience Prognosticky stratifikovaná liečba difuzního velkobuněčního lymfou : 13 leté skušenosti z Moravy. (cs) Prognosticaly stratified treatment of diffuse large B-Cell lymphoma: 13 years of the Moravian experience (en)
skos:prefLabel	Prognosticaly stratified treatment of diffuse large B-Cell lymphoma: 13 years of the Moravian experience Prognosticky stratifikovaná liečba difuzního velkobuněčního lymfou : 13 leté skušenosti z Moravy. (cs) Prognosticaly stratified treatment of diffuse large B-Cell lymphoma: 13 years of the Moravian experience (en)
skos:notation	RIV/61989592:15110/08:00006210!RIV09-MZ0-15110___
http://linked.open...avai/riv/aktivita	P Z
http://linked.open...avai/riv/aktivity	P(NR9502), Z(MSM6198959205)
http://linked.open...iv/cisloPeriodika	1
http://linked.open...vai/riv/dodaniDat	2009
http://linked.open...aciTvurceVysledku	Raida, Luděk Vondráková, Jana PAPAJÍK, Tomáš Hluší, Antonín MYSLIVEČEK, Miroslav Faber, Edgar INDRÁK, Karel Procházka, Vít Kučerová, Ladislava Szotkowski, Tomáš Urbanová, Renata
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Lékařská fakulta
http://linked.open...dnocenehoVysledku	390194
http://linked.open...ai/riv/idVysledku	RIV/61989592:15110/08:00006210
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Diffuse large B-cell lymphoma (DLBCL); non-Hodgkin lymphoma; prognostic factors (en)
http://linked.open.../riv/klicoveSlovo	Diffuse large B-cell lymphoma (DLBCL) prognostic factors non-Hodgkin lymphoma
http://linked.open...odStatuVydavatele	IT - Italská republika
http://linked.open...ontrolniKodProRIV	[6E28FF5DEB3C]
http://linked.open...i/riv/nazevZdroje	Haematologica: the hematology journal
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	11 (xsd:int)
http://linked.open...cetTvurcuVysledku	14 (xsd:int)
http://linked.open...vavai/riv/projekt	Integrated 2-[fluorine-18] fluoro-2-deoxy-D-glucose positron emission tomography with computer tomography as basic imaging method for the evaluation of non-Hodgkin´s lymphoma patients
http://linked.open...UplatneniVysledku	2008
http://linked.open...v/svazekPeriodika	93
http://linked.open...iv/tvurceVysledku	Faber, Edgar Indrák, Karel Kubová, Zuzana Raida, Luděk Vondráková, Jana Hluší, Antonín Procházka, Vít Pavlík, T. Kučerová, Ladislava Papajík, Tomáš Szotkowski, Tomáš Mysliveček, Miroslav Urbanová, Ranata Štícha, M.
http://linked.open...n/vavai/riv/zamer	Studies of genes and molecular mechanisms involved in regulation of hematopoiesis, their clinical impact and targeted treatment
issn	0390-6078
number of pages	1 (xsd:int)
http://localhost/t...ganizacniJednotka	15110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 82 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software